The Gynecologic Oncology Group (GOG) is a premier multidisciplinary, multimodal clinical trial research program investigating new therapeutic approaches in the management of gynecologic malignancies. The GOG Tissue Bank, through the Tissue Utilization Subcommittee of the Committee on Experimental Medicine, is an integral part of this program. Since 2003, the GOG Tissue Bank has received and processed specimens from close to 46,000 patients enrolled at over 250 institutions. The Bank also distributed over 81,000 specimens to 215 investigators, resulting in 122 scientific papers. This is reflective of improved access by investigators to the GOG Tissue Bank via NCI web sites and networking of investigators via the Cooperative Human Tissue Network. The GOG Tissue Bank monitors and modifies its tissue procurement and distribution technologies to meet changing investigator needs. This is evidenced by the introduction of tissue microarray and virtual microscopy technologies during the last grant cycle, Our Specific Aims are;1. To extend the spectrum of molecular research in gynecologic cancer via expanded procurement of not only ovarian, but also cervical, uterine, primary peritoneal and rare gynecologic malignancies. 2. To enhance biospecimen data collection and exchange with the Statistical Data Center and all participating GOG disciplines and committees to advance translational research and high-impact discoveries. 3. To extend the spectrum of virtual microscopy and digital pathology for gynecologic cancer via expanded participation, use, and functionality of the technology 4. To continue to expand tissue-based technologies including nucleic acid extractions and tissue microarrays (TMAs) to facilitate molecular research. 5. To harmonize with other Cooperative Group Banks through NCI Group Banking Committee initiatives to simplify investigators'access to biospecimens and associated data.
The Gynecologic Oncology Group (GOG) Tissue Bank receives processes and stores gynecologic cancer specimens from patients enrolled on GOG clinical trials. These specimens are then distributed to investigators across the United States and Canada for use in medical research. The results of this research range from gaining new insights into how cancers develop and progress to the efficacy of new therapeutic regiments.
|Winder, Abigail D; Maniar, Kruti P; Wei, Jian-Jun et al. (2016) Synuclein-Î³ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer :|
|Eskander, Ramez N; Ali, Shamshad; Dellinger, Thanh et al. (2016) Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer 26:125-32|
|Norquist, Barbara M; Harrell, Maria I; Brady, Mark F et al. (2016) Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol 2:482-90|
|Garcia-Soto, Arlene E; Java, James J; Nieves Neira, Wilberto et al. (2016) Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol 143:484-489|
|Swisher, Elizabeth M; Harrell, Maria I; Norquist, Barbara M et al. (2016) Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. JAMA Oncol 2:370-2|
|McMeekin, D Scott; Tritchler, David L; Cohn, David E et al. (2016) Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 34:3062-8|
|Monk, Bradley J; Facciabene, Andrea; Brady, William E et al. (2016) Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy. Clin Cancer Res :|
|Goodfellow, Paul J; Billingsley, Caroline C; Lankes, Heather A et al. (2015) Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol 33:4301-8|
|Bender, David; Sill, Michael W; Lankes, Heather A et al. (2015) A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138:507-12|
|Powell, Matthew A; Sill, Michael W; Goodfellow, Paul J et al. (2014) A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:38-43|
Showing the most recent 10 out of 13 publications